Evidence map›Paper›PMID 41045935›Full record

ArticleCell reports. Medicine2025

Comprehensive dissection of rectal cancer organoids in responses to chemoradiation.

Xiaoya Xu, Tao Lv, Ye Yao, Juefeng Wan, Lijun Shen, Fan Xia, Xiaoxue Gao, Yuanchuang Li, Guoxiang Fu, Yun Deng and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Xiaoya XuInstitute of Radiation Medicine, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Tao LvDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Ye YaoDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. Electronic address: yaoye@sysucc.org.cn.
Juefeng WanDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Lijun ShenDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Fan XiaDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Xiaoxue GaoInstitute of Radiation Medicine, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Yuanchuang LiInstitute of Radiation Medicine, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Guoxiang FuInstitute of Radiation Medicine, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Yun DengDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai 230032, China.
Mengxue PanInstitute of Radiation Medicine, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Qiang GuoInstitute of Radiation Medicine, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Xinxin RaoInstitute of Radiation Medicine, Shanghai Medical College, Fudan University, Shanghai 200032, China; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Peiyuan TangInstitute of Radiation Medicine, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Xiaomeng LiInstitute of Radiation Medicine, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Yi ZhouInstitute of Radiation Medicine, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Liping LiangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Radiation Oncology Center, Huashan Hospital, Fudan University, Shanghai 200040, China.
Yaqi WangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Jing ZhangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Hui ZhangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Guichao LiDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Min ChenAPExBIO Technology LLC, Shanghai 200438, China.
Junjie PengDepartment of Colorectal Cancer, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Sanjun CaiDepartment of Colorectal Cancer, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Cancer Institute, Fudan University Shanghai Cancer Center Fudan University, Shanghai 200032, China.
Jianjun GaoInstitute of Radiation Medicine, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Guoqiang HuaDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai 230032, China.
Zhen ZhangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. Electronic address: zhenzhang6@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The responses of cancer organoids to treatments in vitro can predict the clinical outcomes of corresponding patients. Here, we further uncover that the responses of cancer organoids to combined treatments predict the clinical outcomes of locally advanced rectal cancer (LARC) patients more faithfully than monotherapy with 92.50% and 93.75% accuracy in the discovery and validation cohorts, respectively, which is partly due to the synergistic (3.91%, 5/128) and antagonistic (4.69%, 6/128) treatment interactions in combined chemoradiation. In addition, our detailed analysis reveals that the time point for collecting survival data of organoids is critical to the efficacy of organoids' responses to treatments for predicting the clinical outcomes of LARC patients. Besides, our current data favor the addition of irinotecan for neoadjuvant treatment of LARC patients. The comprehensive dissection of rectal cancer organoids in responses to chemoradiation here may have significant implications for the broad application of organoids in cancer precision treatments.

Indexed as

ChemoradiotherapyOrganoidsRectal NeoplasmsFemaleHumansIrinotecanMaleTreatment OutcomeIrinotecanchemotherapyirinotecanorganoidrectal cancer

Identifiers

PMID41045935
PMCPMC12629783

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.